These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26965699)

  • 1. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.
    Swisher SK; Wu Y; Castaneda CA; Lyons GR; Yang F; Tapia C; Wang X; Casavilca SA; Bassett R; Castillo M; Sahin A; Mittendorf EA
    Ann Surg Oncol; 2016 Jul; 23(7):2242-8. PubMed ID: 26965699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interobserver reproducibility of tumor-infiltrating lymphocyte evaluations in breast cancer.
    Cabuk FK; Aktepe F; Kapucuoglu FN; Coban I; Sarsenov D; Ozmen V
    Indian J Pathol Microbiol; 2018; 61(2):181-186. PubMed ID: 29676353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
    Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
    Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    O'Loughlin M; Andreu X; Bianchi S; Chemielik E; Cordoba A; Cserni G; Figueiredo P; Floris G; Foschini MP; Heikkilä P; Kulka J; Liepniece-Karele I; Regitnig P; Reiner A; Ryska A; Sapino A; Shalaby A; Stovgaard ES; Quinn C; Walsh EM; Zolota V; Glynn SA; Callagy G
    Breast Cancer Res Treat; 2018 Aug; 171(1):1-9. PubMed ID: 29774470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.
    Tian T; Ruan M; Yang W; Shui R
    Oncotarget; 2016 Jul; 7(28):44395-44405. PubMed ID: 27323808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists.
    Tramm T; Di Caterino T; Jylling AB; Lelkaitis G; Lænkholm AV; Ragó P; Tabor TP; Talman MM; Vouza E;
    Acta Oncol; 2018 Jan; 57(1):90-94. PubMed ID: 29168428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014.
    Kojima YA; Wang X; Sun H; Compton F; Covinsky M; Zhang S
    Ann Diagn Pathol; 2018 Aug; 35():77-79. PubMed ID: 29886396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage.
    Pujani M; Jain H; Chauhan V; Agarwal C; Singh K; Singh M
    Breast Dis; 2020; 39(2):61-69. PubMed ID: 32310155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
    Adams S; Gray RJ; Demaria S; Goldstein L; Perez EA; Shulman LN; Martino S; Wang M; Jones VE; Saphner TJ; Wolff AC; Wood WC; Davidson NE; Sledge GW; Sparano JA; Badve SS
    J Clin Oncol; 2014 Sep; 32(27):2959-66. PubMed ID: 25071121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
    Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hotspot enumeration of CD8+ tumor-infiltrating lymphocytes using digital image analysis in triple-negative breast cancer yields consistent results.
    McIntire PJ; Zhong E; Patel A; Khani F; D'Alfonso TM; Chen Z; Shin SJ; Ginter PS
    Hum Pathol; 2019 Mar; 85():27-32. PubMed ID: 30381263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
    Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
    Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer.
    Eryilmaz MK; Mutlu H; Ünal B; Salim DK; Musri FY; Coşkun HŞ
    J Cancer Res Ther; 2018; 14(3):619-624. PubMed ID: 29893329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Infiltrating Lymphocytes in Breast Cancer: Evaluating Interobserver Variability, Heterogeneity, and Fidelity of Scoring Core Biopsies.
    Khoury T; Peng X; Yan L; Wang D; Nagrale V
    Am J Clin Pathol; 2018 Oct; 150(5):441-450. PubMed ID: 30052720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter-observer agreement of tumor infiltrating lymphocytes in primary HER2-positive breast cancer and correlation between tissue microarray and full tumor-sections.
    Reznitsky FM; Jensen JD; Knoop A; Laenkholm AV
    APMIS; 2022 Sep; 130(9):545-550. PubMed ID: 35639634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
    Loi S; Michiels S; Salgado R; Sirtaine N; Jose V; Fumagalli D; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Desmedt C; Piccart MJ; Loibl S; Denkert C; Smyth MJ; Joensuu H; Sotiriou C
    Ann Oncol; 2014 Aug; 25(8):1544-50. PubMed ID: 24608200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
    Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
    Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.